GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-β

Sarcomas are mesenchymal cancers with poor prognosis, representing about 20% of all solid malignancies in children, adolescents, and young adults. Radio- and chemoresistance are common features of sarcomas warranting the search for novel prognostic and predictive markers. GARP/LRRC32 is a TGF-β-acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Carrillo-Gálvez, Ana Belén, Quintero, Juan Esteban, Rodríguez, René, Menéndez, Sofía T., Victoria González, M., Blanco-Lorenzo, Verónica, Allonca, Eva, de Araújo Farias, Virgínea, González-Correa, Juan Elías, Erill-Sagalés, Nadina, Martínez-Zubiaurre, Iñigo, Hellevik, Turid, Sánchez-Hernández, Sabina, Muñoz, Pilar, Zurita, Federico, Martín, Francisco, Rodríguez-Manzaneque, Juan Carlos, Anderson, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673987/
https://www.ncbi.nlm.nih.gov/pubmed/33203838
http://dx.doi.org/10.1038/s41419-020-03197-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673987/
https://www.ncbi.nlm.nih.gov/pubmed/33203838
http://dx.doi.org/10.1038/s41419-020-03197-z

Ejemplares similares